MariMed Q2 revenue rises on wholesale, retail segment strength
MRMD•Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the drug retailers peer group is "buy".
Wall Street's median 12-month price target for MariMed Inc is $0.08, about 14.8% above its August 11 closing price of $0.07.
Outlook and strategy
MariMed said it will continue its "Expand the Brand" strategy, focusing on product innovation and market expansion.
The company also said it is monitoring potential regulatory changes that could affect the industry.
Quarterly revenue and loss details
MariMed said second-quarter revenue rose year over year to a record high, driven by gains in both wholesale and retail businesses.
| Metric | Actual | Consensus Estimate |
|---|---|---|
| Q2 Revenue | $41.90 mln | $39.80 mln (1 Analyst) |
| Q2 Adjusted Net Loss | $2.40 mln | $3.90 mln (1 Analyst) |
| Q2 Net Loss | $3.60 mln | |
| Q2 Adjusted EBITDA | $3.90 mln | $4 mln (1 Analyst) |
| Q2 Gross Margin | 39.00% | |
| Q2 Adjusted EBITDA Margin | 9.4% | |
| Q2 Adjusted Gross Margin |
Related News
Transwestern Investments, Balcones form joint venture for 328,256-sq-ft Kyle Commerce Center development in Texas
XLRE•
Pearl Diver Credit Estimates Unaudited NAV Per Share As Of July 31, 2026 At $10.96
PDCC•
